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The Tumor Necrosis Factor Superfamily Molecule
LIGHT Promotes Keratinocyte Activity and Skin Fibrosis
Rana Herro1, Ricardo Da S. Antunes1, Amelia R. Aguilera1, Koji Tamada2 and Michael Croft1
Several inﬂammatory diseases including scleroderma and atopic dermatitis display dermal thickening, epidermal
hypertrophy, or excessive accumulation of collagen. Factors that might promote these features are of interest for
clinical therapy. We previously reported that LIGHT, a TNF superfamily molecule, mediated collagen deposition
in the lungs in response to allergen. We therefore tested whether LIGHT might similarly promote collagen
accumulation and features of skin ﬁbrosis. Strikingly, injection of recombinant soluble LIGHT into naive mice,
either subcutaneously or systemically, promoted collagen deposition in the skin and dermal and epidermal
thickening. This replicated the activity of bleomycin, an antibiotic that has been previously used in models of
scleroderma in mice. Moreover skin ﬁbrosis induced by bleomycin was dependent on endogenous LIGHT
activity. The action of LIGHT in vivo was mediated via both of its receptors, HVEM and LTβR, and was dependent
on the innate cytokine TSLP and TGF-β. Furthermore, we found that HVEM and LTβR were expressed on human
epidermal keratinocytes and that LIGHT could directly promote TSLP expression in these cells. We reveal an
unappreciated activity of LIGHT on keratinocytes and suggest that LIGHT may be an important mediator of skin
inﬂammation and ﬁbrosis in diseases such as scleroderma or atopic dermatitis.
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INTRODUCTION
Fibrosis and thickening of the skin are characteristics of
several inﬂammatory and autoimmune diseases including
scleroderma and atopic dermatitis (Boin and Wigley, 2009;
Yamamoto, 2009; Rosenbloom et al., 2010; Wynn and
Ramalingam, 2012). Current treatments involve non-
selective immunotherapy with corticosteroids, D-penicilla-
mine, methotrexate, or cyclophosphamide, but deﬁning new
targets for intervention of ﬁbrosis in the skin is important.
Fibrosis is a feature that is shared with other diseases such as
severe asthma, and autoimmune diseases like rheumatoid
arthritis, Crohn’s disease, and systemic lupus erythematosus,
but whether there are common molecules that promote
clinical symptoms across these syndromes is not clear. Recent
studies of thymic stromal lymphopoietin (TSLP) have sug-
gested that it may be central to ﬁbrosis in a number of
different tissues (Yoo et al., 2005; Comeau and Ziegler, 2010;
Ziegler and Artis, 2010). Transgenic expression of TSLP in
keratinocytes resulted in spontaneous development of
features of atopic dermatitis or scleroderma, and transgenic
expression of TSLP in lung epithelial cells promoted lung
ﬁbrosis characteristic of severe asthma (Yoo et al., 2005; Zhou
et al., 2005). Furthermore, human keratinocytes in the skin of
patients with atopic dermatitis or systemic sclerosis/
scleroderma express high levels of TSLP, and elevated TSLP
is also seen in asthmatics (Ying et al., 2008; Alysandratos
et al., 2010; Lee et al., 2010; Shikotra et al., 2012; Sano et al.,
2013; Yao et al., 2013). This suggests that there may be shared
mechanisms that drive some of the features of these diseases.
In this regard, we showed that tumor necrosis factor (TNF)
superfamily member 14 (TNFSF14), known as LIGHT or
CD258 (Ware, 2005,2009), strongly promoted ﬁbrosis in the
lungs of mice chronically challenged with allergen (Doherty
et al., 2011). Here, we now show that LIGHT can similarly
promote ﬁbrotic features in the skin. Direct injection of
recombinant LIGHT into naive mice promoted dermal and
epidermal thickening. In addition, ﬁbrotic features in the skin
were abrogated in LIGHT-deﬁcient mice treated with
bleomycin in a mouse model that produces symptoms
reminiscent of those exhibited in scleroderma (Yamamoto
and Nishioka, 2005; Yamamoto, 2006). Importantly, the
action of LIGHT was dependent on activity of TSLP, and also
transforming growth factor-β (TGF-β), and stimulation of
keratinocytes with recombinant LIGHT promoted TSLP
expression. These data further the contention that LIGHT
may be central to ﬁbrosis in multiple tissues and may be
amenable to clinical targeting in diseases of the skin.
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RESULTS
Soluble recombinant LIGHT induces features of skin ﬁbrosis
Our prior studies in mice chronically challenged with
allergen, in models of asthma, showed that LIGHT was
endogenously produced in the lungs and contributed to lung
ﬁbrosis and tissue remodeling. Moreover, intratracheal injec-
tion of an amount of ~ 10 μg of recombinant LIGHT, into
acutely allergen-challenged animals, mimicked tissue remo-
deling in the lungs of chronically allergen-challenged animals
(Doherty et al., 2011). We therefore asked whether recom-
binant LIGHT was able to drive similar ﬁbrotic features in the
skin, and whether this could occur in the absence of other
inﬂammatory stimuli. We injected recombinant LIGHT or
phosphate-buffered saline (PBS) twice, either subcutaneously
(SC) or intratracheally (IT). The latter route was used based on
our prior results in the lung studies (Doherty et al., 2011), and
with the notion that LIGHT might become systemic and lead
to activity in the skin, of possible relevance to the link that has
been described in humans between allergic responses in the
lungs and skin.
Impressively, LIGHT injection led to collagen deposition in
the skin, as assessed with Masson’s trichrome stain, penetrat-
ing into the adipose layer, regardless of whether the SC or IT
route was used (Figure 1a). In line with this, we found that
total skin collagen, as assessed by the sircol assay, was
increased by an average of 34% in mice injected with LIGHT
when compared with mice injected with PBS (data not
shown). Epidermal activity was also obvious with pronounced
keratinocyte hypertrophy (Figure 1a), and quantitation of
epidermal and dermal thickening further conﬁrmed a
pronounced activity of LIGHT (Figure 1b). A strong increase
in staining of alpha smooth muscle actin (α-SMA) was also
seen in skin sections, particularly in cells with the morphology
of basal keratinocytes in the hair follicles (Figures 1a and c), in
line with prior reports that these cells can express α-SMA
(Jahoda et al., 1991; Latorre et al., 2013; Li et al., 2014). Other
cells that were likely myoﬁbroblasts also expressed α-SMA,
based on staining for the marker ER-TR7 (Figure 1c). Some
vascular changes were additionally observed with the
endothelial wall of skin blood vessels also expressing
increased α-SMA in animals injected with LIGHT (Figures
1a and c). We additionally observed a low level of immune
cellular inﬁltration into the skin in some mice, including
macrophages, neutrophils, and T-cells, although overall this
was only statistically signiﬁcant when LIGHT was injected SC
(Figure 1d). qPCR analysis conﬁrmed upregulation of collagen
and α-SMA transcripts, as well as TGF-β1, which is often
associated with ﬁbrotic activity, with both SC and IT injection
(Figure 1e).
Reduced skin ﬁbrotic activity in LIGHT-deﬁcient mice
To determine whether endogenous LIGHT activity could
contribute to ﬁbrotic features in the skin, we used an esta-
blished model with the antibiotic bleomycin that produces
symptoms in mouse skin that has features in common with the
skin of patients with scleroderma (Yamamoto and Nishioka,
2005; Yamamoto, 2006). Interestingly, the phenotype in the
skin of wild-type (WT) mice promoted by bleomycin was
histologically similar to that induced by injection of recombi-
nant LIGHT. Importantly, bleomycin-treated LIGHT− /− mice
failed to accumulate signiﬁcant amounts of collagen with little
evidence of trichrome stain in the sub-dermal adipose layer
(Figure 2a). Total skin collagen, based on the sircol assay, was
increased with a mean of 38% in WT mice given bleomycin
over those given PBS, whereas a mean increase of only 13%
was seen in LIGHT− /− mice. Alpha smooth muscle actin
expression was also not upregulated to any great extent in
LIGHT− /− mice and a decrease in skin angiogenesis was also
observed in these mice (Figure 2a). Moreover, quantitation
of both dermal and epidermal thickening revealed a very
pronounced activity of bleomycin in WT mice with markedly
less in LIGHT− /− mice (Figure 2b). Cellular inﬁltration was
moderately reduced in LIGHT-deﬁcient mice compared with
WT mice with an overall trend to fewer dendritic cells,
macrophages, neutrophils, and T-cells (Figure 2c). These data
demonstrate a primary role for endogenously produced
LIGHT in driving skin ﬁbrosis and also substantiate the
conclusion that the prior results with injection of recombinant
LIGHT into naive mice (Figure 1) produced a physiologically
relevant effect.
Both LTβR and HVEM contribute to skin ﬁbrosis and thickening
LIGHT binds to two receptors—LTβR/TNFRSF3 and HVEM/
TNFRSF14. To understand whether one or both of these
molecules were involved, we assessed responses in WT mice
treated with an antibody that selectively neutralizes LIGHT–
LTβR interactions and also tested responses in HVEM− /− mice.
In naive mice injected with recombinant LIGHT, epidermal
thickening and hypertrophy of keratinocytes were almost
completely abrogated with deletion of HVEM or with blocking
LTβR. In contrast, dermal ﬁbrosis was reduced to a much
greater extent in the absence of HVEM interactions. Blocking
LIGHT–LTβR still reduced dermal and sub-dermal collagen
slightly but to a markedly lesser degree (Figure 3a). α-SMA
expression was also reduced when either LIGHT–HVEM or
LIGHT–LTβR interaction was neutralized (Figure 3b). Impor-
tantly, almost identical results were obtained in mice treated
with bleomycin with epidermal thickening and α-SMA accu-
mulation being regulated by both LTβR and HVEM and dermal
thickening more dependent on HVEM (Figures 3a and b).
LIGHT upregulates TSLP in vivo to promote skin ﬁbrosis
Given the prominent role suggested for TSLP in promoting
skin ﬁbrosis when overexpressed in transgenic mice (Yoo
et al., 2005) and data that found TSLPR− /− mice did not
develop pronounced skin ﬁbrosis induced by subcutaneous
injection of bleomycin (Usategui et al., 2013), we determined
whether LIGHT might control TSLP expression. Signiﬁcantly,
in naive mice injected with rLIGHT, we found upregulated
expression of TSLP mRNA within 2 days in the skin
(Figure 4a). Again, this was regardless of administration SC
or IT. Importantly, induction of TSLP protein was easily
visualized by immunohistochemistry in the skin, largely
expressed in keratinocytes in both the epidermis and hair
follicles (Figure 4a). To extend this, we found a similar lack of
the skin ﬁbrotic phenotype in TSLPR− /− mice as observed in
R Herro et al.
LIGHT Promotes Skin Fibrosis
2110 Journal of Investigative Dermatology (2015), Volume 135
LIGHT− /− mice (Figure 4b) and found a marked reduction in
TSLP protein in the skin of bleomycin-treated LIGHT− /− mice
(Figure 4c). We further showed that essentially all of the
hallmarks of disease, including collagen deposition and
dermal and epidermal thickening, as well as α-SMA
accumulation, were abrogated when LIGHT was injected
into TSLPR− /− mice (Figure 4d).
LIGHT synergizes with TGF-β in vivo to promote TSLP
expression and skin ﬁbrosis
Recombinant LIGHT promoted TGF-β expression in the skin
(Figure 1). In accordance, we also found reduced TGF-β
mRNA levels in the skin of LIGHT− /− mice, WT mice treated
with anti-LTβR, and HVEM− /− mice injected with bleomycin
(Figure 5a). As this cytokine has been implicated in ﬁbrotic
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Figure 1. Recombinant LIGHT induces skin ﬁbrosis in naive mice. Naive wild-type (WT) mice were injected with 10 μg of soluble rmLIGHT or phosphate-
buffered saline (PBS) alone, administered subcutaneously (SC, on the back between the ears) or intratracheally (IT) on days 1 and 2. Skin inﬂammation and ﬁbrosis
were assessed 24 h later on day 3. (a–c) (a) Skin sections (original magniﬁcation ×20) were stained with Masson’s trichrome (top, blue) or an antibody to alpha
smooth muscle actin (α-SMA; bottom, red, DAPI blue). Dashed line in immunoﬂuorescent images delineates the basement membrane. (b) Quantiﬁcation of
epidermal and dermal thickening. Values from individual tissues from 5 mice. (c) Higher power images of the following: Left: LIGHT-injected skin section
co-stained with ER-TR7 (green) and α-SMA (red). Yellow arrows indicate ER-TR7/α-SMA-positive cells (white). Right top: Hair follicle in LIGHT-injected skin
stained with α-SMA (red). Right bottom: blood vessels from PBS or LIGHT-injected skin sections stained for α-SMA (red). Bar= μm. Data are representative of six
experiments. (d) Total CD45+ cells, dendritic cells (DC), neutrophils, macrophages, and T-cells were enumerated in skin biopsies that included both the dermis
and epidermis. Values are from individual tissues from six mice. (e) quantitative reverse transcriptase in real time (qPCR) analysis of skin samples for mRNA of
collagen, α-SMA, and transforming growth factor-β (TGF-β) calculated relative to L32. Values are mean± SEM from 2 to 4 mice per condition. NS, not signiﬁcant;
*Po0.05; **Po0.1; ***Po0.01; ****Po0.001.
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activity in many situations, we then neutralized TGF-β
signaling in vivo. We observed a signiﬁcant reduction in
collagen deposition and α-SMA accumulation, as well as
interestingly a lower level of TSLP expression in the skin
(Figure 5b). This suggests that LIGHT and TGF-β synergized to
promote TSLP or LIGHT indirectly promoted TSLP through
TGF-β.
LIGHT directly induces TSLP in keratinocytes independently of
TGF-β
Because the primary source of TSLP in the skin appeared to be
keratinocytes, we then asked whether human and mouse
keratinocytes expressed the receptors for LIGHT and might
directly respond by producing TSLP. Signiﬁcantly, LTβR and
HVEM were constitutively expressed on normal human
epidermal keratinocytes and a mouse keratinocyte cell line
(Figure 6a). Furthermore, recombinant human LIGHT or
mouse LIGHT strongly induced the expression of TSLP mRNA
in the human and mouse keratinocytes, and TSLP protein was
also detected by immunoﬂuorescence (Figure 6b). Moreover,
blocking TGF-β in these cultures did not ablate TSLP expres-
sion by keratinocytes (Figure 6c). Together with the in vivo
data in Figure 5, this suggests that LIGHT can both directly
induce TSLP from keratinocytes and can also co-operate with
TGF-β to further control TSLP production.
Finally, as LIGHT promoted epidermal thickening in vivo,
we asked whether it could directly induce keratinocyte
proliferation/hyperplasia or hypertrophy. Staining of skin
tissue sections for Ki67, a protein associated with cell
division, did reveal that some, although not all, epidermal
keratinocytes expressed this molecule in mice injected with
rLIGHT (not shown), implying that epidermal thickening was
likely the result of both hypertrophy and hyperplasia.
However, BrdU and 7AAD analysis of keratinocytes did not
show any evidence of enhanced proliferation when stimu-
lated with LIGHT in vitro, and no obvious increase in cell size
(not shown). As data in TSLPR− /− mice, and with blocking
TGF-β, showed a lack of epidermal thickening (Figures 4 and
5), this suggests that LIGHT primarily acted indirectly through
these or other cytokines to drive hypertrophy and hyperplasia
of keratinocytes in vivo. Nevertheless, we cannot exclude the
possibility that direct LIGHT signaling in keratinocytes might
promote these activities in synergy with another molecule.
DISCUSSION
Understanding the molecules that directly promote ﬁbrosis or
might drive activity of other ﬁbrotic factors may prove useful
for future therapeutic approaches. We now show that LIGHT
as a soluble molecule can very rapidly induce a ﬁbrotic
phenotype in the skin even in the absence of any other
stimulus and can promote the scleroderma- or atopic
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Figure 2. LIGHT-deﬁcient mice exhibit decreased skin ﬁbrosis induced by bleomycin. wild-type (WT) and LIGHT− /− mice were administered 0.2 U bleomycin
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dermatitis-like phenotype that is characteristic of skin disease
driven by bleomycin. Moreover, LIGHT controlled the
production of TSLP and TGF-β in the skin and directly
induced TSLP expression by keratinocytes.
Our ﬁnding that recombinant LIGHT alone could induce
ﬁbrosis in the skin, and LIGHT-deﬁcient mice displayed
defective skin ﬁbrotic activity, suggests it is an important
mediator of the complex inﬂammatory response that can
result in this organ. Moreover, the fact that the activity of
LIGHT was in part mediated by controlling TSLP expression
provides more evidence of the potential importance of LIGHT
in clinical skin disease. TSLP was shown to be a central
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regulator or inducer of allergic inﬂammation some time ago,
and a strong role of TSLP in the generation of Th2-type
responses has been documented in many models (Comeau
and Ziegler, 2010; Ziegler and Artis, 2010; Ziegler, 2010).
Blocking TSLP, or studies of mice deﬁcient in TSLPR have
shown roles in the development of inﬂammatory responses in
the lung and skin implying commonalities in immune
regulation between these tissues, with the primary sources
of TSLP being thought to be epithelial cells. In line with this,
transgenic mice where TSLP was overexpressed in bronchial
epithelium or in keratinocytes exhibited tissue remodeling
in those organs (Yoo et al., 2005; Zhou et al., 2005).
Furthermore, neutralization of TSLP signaling in a model of
atopic dermatitis also resulted in a strong reduction in skin
ﬁbrosis (Zhu et al., 2011), and the data here and elsewhere
(Usategui et al., 2013) show its important role in promoting
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skin ﬁbrosis triggered by bleomycin. Given the connection we
now show between LIGHT and TSLP, it will then be important
in the future to determine whether LIGHT is elevated together
with TSLP in samples from patients with skin or lung ﬁbrotic
disorders. Recently, it was found that TSLP was highly
expressed in skin lesions of patients with systemic sclerosis
(Usategui et al., 2013), and a GWAS found an association
between genetic variants in TSLP and atopic dermatitis (Gao
et al., 2010). LIGHT was shown to be upregulated in the
plasma of atopic dermatitis patients, and levels reduced coin-
cidently with improvement in clinical dermatitis symptoms in
the patients treated with topical steroids (Kotani et al., 2012).
In addition, microarray analysis found that LIGHT was
upregulated in patients with Alopecia areata, a syndrome to
which atopic dermatitis patients have an increased risk (Coda
and Sinha, 2011). However, more expression and association
data will be essential for substantiating the notion that
production of LIGHT is characteristic of human scleroderma
or atopic dermatitis.
The sources of LIGHT that drive ﬁbrotic activity are not
known at present. Similar to many molecules in the TNF
superfamily, LIGHT is not constitutively expressed. It was ﬁrst
described as a product of activated T-cells (Mauri et al., 1998)
but has also been found to be made by NK cells, dendritic
cells, and macrophages in some conditions (Ware, 2005,
2009). LIGHT might also be produced by other, as yet
unidentiﬁed, cells. Bleomycin induces tissue injury and has
been shown to induce modiﬁcation of self-antigens, such as
cleavage of topoisomerase I (Yamamoto and Nishioka, 2005;
Yamamoto, 2006, 2009). Moreover, apoptosis is detected in
the skin of human systemic sclerosis patients associated with
the severity of tissue damage (Yamamoto and Nishioka, 2005;
Yamamoto, 2009; Yoshizaki et al., 2010). Therefore, many of
the above immune-cell types could be activated to produce
LIGHT during the development of a skin inﬂammatory
response.
Our results suggest that the action of LIGHT in promoting
collagen and α-SMA accumulation in the skin may be largely
indirect through enhancing TSLP and TGF-β expression. For
LIGHT to be involved in a ﬁbrotic response in the skin, its
receptors obviously need to be expressed. T-cells, dendritic
cells, and stromal cells are well known to express either
HVEM and/or LTβR. However, most relevant to ﬁbrosis in the
skin may be either resident immune cells, such as dermal
dendritic cells, macrophages, and ﬁbroblasts, or—as we focus
on in this study—keratinocytes. By identifying TSLP as a
downstream product of LIGHT activity in keratinocytes, and
TSLP as being a major mediator of the pro-ﬁbrotic effects of
LIGHT in vivo, strongly suggests that there will be a central
role of LTβR or HVEM expressed in the epidermis in
contributing to the clinical manifestations of skin ﬁbrosis.
Future studies of mice where LTβR or HVEM are conditionally
deleted in keratinocytes will, however, be required to directly
show the importance of these molecules on this cell type
in vivo.
Our current results also reveal that LIGHT additionally
promoted TGF-β expression in the skin, and that TGF-β was
essential for the ﬁbrotic activity of LIGHT, as well as
contributing to the expression of TSLP in vivo. However,
LIGHT induction of TSLP from keratinocytes was TGF-β
independent, suggesting that another source of TGF-β is likely
to synergize with LIGHT in vivo. Previous work from our
laboratory found that LIGHT could promote TGF-β expression
in lung macrophages that was associated with tissue
remodeling in the lungs (Doherty et al., 2011). Thus,
macrophages in the skin may also be a primary source of
TGF-β, although other cell types could equally be receptive to
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LIGHT signals. Fibroblasts can additionally produce TGF-β,
and dermal ﬁbroblasts were shown to express HVEM in
cutaneous T-cell lymphoma patients (Miyagaki et al., 2012),
and LTβR expression has been seen on lung ﬁbroblasts or
synovial ﬁbroblasts (Mackay et al., 1996; Pierer et al., 2007;
Ishida et al., 2008). Therefore, dermal ﬁbroblasts may also be
a source of TGF-β directly induced by LIGHT.
Likewise, TSLP may have multiple targets in contributing to
skin ﬁbrosis, and its action could be both direct and indirect.
TSLPR can be expressed on dendritic cells, T-cells, natural
killer T-cells, eosinophils, mast cells, and innate lymphoid
cells (Ziegler and Artis, 2010). TSLPR was also found on
ﬁbrocytes/ﬁbroblasts, and when stimulated with TSLP they
produced collagen. Neutralization of TSLP or genetic deletion
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Figure 6. LIGHT induces thymic stromal lymphopoietin (TSLP) in keratinocytes. (a) Human epidermal keratinocytes (HEKn) and mouse PAM212 keratinocytes
were stained for LTβR and HVEM expression by ﬂow cytometry. Isotype control in red. (b) HEKn and PAM212 cells were stimulated in vitro with 100 ngml−1
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of TSLPR in IL-13 transgenic mice also resulted in a signiﬁcant
reduction in the number of ﬁbrocytes and in skin ﬁbrosis (Oh
et al., 2011; Zhu et al., 2011). Furthermore, in a model with
transgenic expression of TSLP in keratinocytes (Yoo et al.,
2005a), upregulation of other molecules that have been found
to contribute to ﬁbrotic activity, such as IL-4, IL-13, and
eotaxin-2, was TSLP dependent. Collectively, this suggests
that there is likely to be a very complex interplay between
many cytokines that ultimately contribute to symptoms
associated with disease of the skin, including that between
LIGHT, TSLP, and TGF-β.
LIGHT is currently being targeted with a human antibody
(SAR252067) in phase II clinical trials for inﬂammatory bowel
disease (Croft et al., 2013). The data here complement our
previous studies, which suggested that LIGHT might be an
attractive target for the therapy of lung ﬁbrosis associated with
asthma, and they expand the potential indications for LIGHT
neutralization to diseases of the skin that are characterized by
ﬁbrosis such as scleroderma and atopic dermatitis.
MATERIALS AND METHODS
Mice
Six- to 8-week-old female WT, LIGHT− /− (from Dr K Pfeffer (Scheu
et al., 2002)), HVEM− /− (from Dr K Pfeffer (Wang et al., 2005)), or
TSLPR− /− mice (from Dr S Ziegler (Carpino et al., 2004)) were bred
in house on the C57BL/6 background. All experiments were in
compliance with the regulations of the La Jolla Institute for Allergy
and Immunology Animal Care Committee.
Experimental protocols
Mice were given 10 μg of recombinant mouse LIGHT (1794-LT/CF,
R&D Systems, Minneapolis, MN) or PBS SC or IT on days 1 and 2 and
killed 1 day later on day 3. Alternatively, mice were challenged with
bleomycin (Sigma, St Louis, MO), 0.2 U per mouse, given IT once,
and monitored for skin inﬂammation and ﬁbrosis after 7 or 14 days.
For neutralization of LIGHT–LTβR interactions, mice were adminis-
tered 200 μg of anti-LTβR mAb (LLTB2; Anand et al., 2006) given i.v.
1 day prior to injection of bleomycin or rLIGHT and every other day
until the end of the experiment. The anti-LTβR mAb (LLTB2)
speciﬁcally blocks binding of LIGHT to LTβR (Anand et al., 2006).
For neutralization of TGF-β, mice were administered 300 μg of anti-
TGF-β mAb (1D11, BioXCell, West Lebanon, NH) given i.p. 1 day
prior to injection of rLIGHT and every other day thereafter.
Quantitative real-time PCR
Total RNA was isolated using TRIzol (Invitrogen, Grand Island, NY).
To further purify RNA from skin samples, we used the RNeasy
Fibrous Tissue mini kit (Qiagen, Valencia, CA, 74704). Single-strand
cDNA was prepared by reverse transcribing 5 μg of total RNA using
the Transcriptor First Strand cDNA kit (Roche, Nutley, NJ). Samples
were ampliﬁed in IQ SYRB Green Supermix (Bio-Rad Laboratories,
Hercules, CA) using the primer pairs: LIGHT: forward, 5′-ACA GCC
TTC AGT GTT TGT GGT G-3′; reverse, 5′-TCC GGT GGT TCT GTT
CCA G-, collagen: forward, 5′-GAG CCC TCG CTT CCG TAC TC-3′;
reverse, 5′-TGT TCC CTA CTC AGC CGT CTG T-3′, α-SMA: forward,
5′-TCT CTA TGC TAA CAA CGT CCT GTCA-3′; reverse, 5′-CCA CCG
ATC CAG ACA GAG TAC TT-3′, TGF-β1: forward, 5′-CCC TAT ATT
TGG AGC CTG GA-3′; reverse, 5′-GGA AGC TTC GGG ATT TAT
GG-3′, muTSLP: forward, 5′-TCG AGG ACT GTG AGA GCA AGC
CAG-3′; reverse, 5′-CTG GAG ATT GCA TGA AGG AAT ACC-3′,
huTSLP: forward, 5′-TAT GAG TGG GAC CAA AAG TAC CG-3′;
reverse, 5′-GGG ATT GAA GGT TAG GCT CTG G-3′. All samples
were run in triplicate, and the mean values were used for
quantiﬁcation.
Collagen and skin thickness measurements
Formalin (4% in PBS)-ﬁxed skin sections were stained with Masson’s
Trichrome to evaluate collagen using an image analysis system
(Image-Pro Plus; Media Cybernetics, Warrendale, PA; Cho et al.,
2004). Epidermal thickness, as well as dermal thickening, was
quantitated using Image Pro Analyser 7 software (Rockville, MD).
Immunohistochemical staining
Skin samples were de-parafﬁnized by sequential placement in xylene
and ethanol. Sections were treated with Fc block in 10% Donkey
serum (in PBS) and stained with (i) rabbit polyclonal antibody to
α-SMA (clone 1A4, ab7817-abcam, Cambridge, MA) at 1:200
concentration followed by Rhodamine Red-X AfﬁniPure Donkey
anti-rabbit (Jackson Immunoresearch, West Grove, PA, 711295152)
at 1:500 and (ii) Goat polyclonal antibody to TSLP (clone L18, Santa
Cruz Biotechnology, Dallas, TX) at 1:200 followed by Donkey
anti-goat IgG-FITC (sc-2024, Santa Cruz Biotechnology) at 1:500.
Slides were read on a Nikon 80i microscope and analyzed by
LSM-Image software (Thornwood, NY).
Analysis of skin immune-cell inﬁltrates
Skin biopsy, including both the dermis and epidermis, was minced in
the presence of trypsin/dispase and collagenase, and cellular
inﬁltration was assessed by ﬂow on isolated skin cells using the
following: CD45.2-BV711 (Clone 104; BD), CD3e-BV650 (Clone
145-2C11; BD), Mac3-Alexa Fluor 647 (Clone M4/84; Biolegend,
San Diego, CA), Ly6-G/Ly6-G-Alexa Fluor 700 (Gr1, clone RB6-8C5;
Biolegend), SiglecF-PE-CF594 (Clone E50-2440; BD), CD11b-BB515
(Clone M1/70; BD), and CD11c-Brilliant Violet 785 (Clone N418;
Biolegend). Macrophages were gated as CD45+, autoﬂuorescent high,
Mac3+, CD11c+, and SiglecF+, Dendritic cells as CD45+, CD11c+, and
CD11b+, Neutrophils as CD45+, GR1+, CD11b+, and Siglec F−and,
T-cells as CD45+ and CD3+.
Stimulation of keratinocytes
Human epidermal keratinocytes from neonates (HEKn; from Dr
Wendy Havran) or a mouse keratinocyte cell line, PAM212, were
stimulated with 100 ngml− 1 of recombinant human LIGHT (R&D,
664-LI/CF) or 20 ngml− 1 mouse LIGHT for 72 h in Epilife media (Life
technologies, Grand Island, NY). TSLP was measured by immunos-
taining, using anti-hTSLP mAb (clone AF1398, from R&D) or anti-
mTSLP (clone 18, Santa Cruz Biotechnology), and qPCR analyses.
For TGF-β neutralization, 30 μgml−1 of anti-TGF-βmAb (1D11) or its
Isotype control were added into culture. LIGHT receptors were
visualized using anti-LTβR and anti-HVEM (Biolegend).
Statistical analyses
Statistical analysis was performed using GraphPad Prism software
(La Jolla, CA). A nonparametric t-test or a Mann–Whitney test was used
where indicated. A P-value of o0.05 was considered statistically
signiﬁcant.
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